In brief
In a significant development for obesity treatment accessibility, President Donald Trump has reached agreements with drug manufacturers Eli Lilly and Novo Nordisk to reduce prices and expand coverage for their GLP-1 receptor agonist medications, Zepbound and Wegovy. Starting next year, Medicare patients will gain access to these drugs, which currently cost around $500 per month without insurance. The administration hopes these moves will alleviate cost-of-living concerns among voters amidst rising healthcare expenses. Doctors are optimistic yet cautious, as many patients continue to struggle with the financial burden of obesity treatment.
WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years.
Access to the drugs has been a consistent problem for patients due to their steep costs — around $500 a month — compounded by inconsistent insurance coverage.
Under the new agreement, Medicare coverage of the drugs for obesity will begin next year, with some lower prices introduced for patients lacking coverage. Additionally, starting doses of new oral versions of the medications are expected to cost $149 per month if approved.
This announcement is part of the Trump administration's ongoing battle to curb rising drug prices in response to voters' cost-of-living concerns. Recent agreements have also seen Pfizer and AstraZeneca lowering prescription drug costs for Medicaid following an executive order setting price reduction deadlines.
However, it remains unclear how significantly these price drops will benefit consumers, given the variable nature of drug pricing related to competition and insurance.
Obesity Drugs Remain Costly Despite Popularity
The GLP-1 obesity drugs work by influencing hormones in the gut and brain that regulate appetite and satiety, with certain clinical trials showing participants losing between 15% and 22% of their body weight.
Most patients initially take smaller doses before increasing to higher amounts according to their treatment requirements. Consequently, they often must rely on long-term use to prevent weight regain, as obesity is now recognized as a chronic disease.
Drugmakers Eli Lilly and Novo Nordisk have seen significant financial benefits from these treatments, with Lilly reporting a threefold increase in Zepbound sales to above $9 billion this year.
Previously, Medicare has not covered obesity treatments, with attempts under former President Joe Biden to change this being rejected by the Trump administration.
Many state and federally funded Medicaid programs offer limited coverage for these treatments, while private insurers remain hesitant due to the high potential demand from patients.
Doctors have pointed out that the $500 monthly cost for higher doses is prohibitive for those without insurance coverage.
Trump's Response to Public Concerns
The drive to lower barriers to accessing popular GLP-1 medications reflects the White House's aim to align Trump with American voters' frustrations regarding the increasing costs of living, especially in the context of recent electoral outcomes that signaled economic concerns influencing voter preferences.
Adopting a critical stance towards the previous administration's approach, the Trump administration claimed to have reached a more advantageous deal for American consumers by ensuring that drug manufacturers participate in price reductions.
The new agreements will see Medicare patients able to obtain medications with copays of only $50, while state and federally funded Medicaid programs will also see price reductions. The administration's TrumpRx program plans to facilitate direct purchases from manufacturers, starting next January.
Medical Community's Perspective on Price Reductions
Dr. Leslie Golden reports that a large portion of her patients, about 75%, struggle to cover their treatment costs, often leading them to seek alternative solutions to finance their prescriptions.
Physicians have expressed cautious optimism, noting the potential significance of Medicare coverage for the 30 million Americans struggling with obesity. However, some healthcare professionals await clearer details before fully endorsing these changes, emphasizing the need for concrete and sustainable solutions for their patients.
Ultimately, healthcare experts highlight the importance of making these highly effective treatments accessible to the obese population, advocating for continued efforts to dismantle financial barriers to effective weight management medications.
